• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
  • Home
  • Investors
  • Shareholders Information

Shareholders Information

Shareholders Information

Equity Threshold (as of September 04, 2023)

Shares Sep 2023

Voting Threshold (as of September 04, 2023)

Voting rights Sep 2023

Total Number of Shares And Voting Rights

Total amount of share capital (EUR) (as of Sep 04, 2023) 80,628,224.49
Total number of shares with single voting rights (as of Sep 04, 2023) 24,156,351
Total number of shares with double voting rights (as of Sep 04, 2023) 2,368,375
Total number of shares (as of Sep 04, 2023) 26,524,726
Total number of voting rights (as of Sep 04, 2023) 28,893,101
Total number of attributed warrants (as of Sep 04, 2023) 2,852,913
Total number of shares with voting rights that could be created following the exercise of the attributed warrants (as of Sep 04, 2023) 2,852,913
Total number of diluted shares (outstanding shares + warrants) (as of Sep 04, 2023) 29,377,639
Total number of diluted shares with voting rights (as of Sep 04, 2023) 31,746,014

Transparency Declarations

13 Sep 2023 Fortress Investment Group LLC
08 Sep 2023 Tolefi SA
05 Sep 2023 Fortress Investment Group LLC
17 Dec 2021 Tolefi SA
13 Dec 2021 Fortress Investment Group LLC
19 May 2021 Victory Capital Management Inc.
05 May 2021 Tolefi SA
28 Sep 2018 Victory Capital Management Inc.

Investor Contact Information:

Investors@celyad.com

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use